BioLife Solutions delivered robust financial performance throughout 2025, with full-year revenue reaching $96.2 million, representing 29% year-over-year growth. The company's fourth quarter results reflected continued momentum, generating $24.8 million in revenue, a 20% increase compared to the same period in 2024. The strong top-line performance was complemented by improved profitability metrics, with the company reporting GAAP net income of $2.1 million in the fourth quarter and adjusted EBITDA of $6.9 million, translating to a 28% adjusted EBITDA margin.
The company's financial trajectory reflects the successful execution of its strategic repositioning. In October 2025, BioLife Solutions completed the divestiture of its evo subsidiary for $25.5 million, a transaction that refocused the organization on its core cell processing operations. This strategic realignment appears to have strengthened operational efficiency, as evidenced by the company's expanding margin profile in the latter half of 2025.
Looking ahead, BioLife Solutions has established conservative guidance for 2026, projecting revenue between $112.5 million and $115 million, which would represent growth of 17% to 20% year-over-year. Notably, the company anticipates achieving full-year GAAP profitability in 2026, signaling management confidence in the sustainability of its operational improvements and continued market expansion in the cell processing sector.